SYNGENESyngene International Limited
Healthcare · Diagnostics & Research · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SYNGENE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 29/100)
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
- • RSI: 39
- • MACD: bearish
Bull case
- • Debt/Equity: 0.09
- • Promoter holding: 52.8%
- • Valuation vs sector: P/E 53.0 vs sector 52.5
- • Volatility: 32% annualized
Bear case
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
- • RSI: 39
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹11.94). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.